Home>
US Stocks>
Mersana Therapeutics Inc

Mersana Therapeutics Inc share price today

(MRSN)

Mersana Therapeutics Inc share price is $2.53 & ₹214.27 as on 7 Dec 2024, 2.30 'hrs' IST

$2.53

▲

0.21

(9.05%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Mersana Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Mersana Therapeutics Inc from India. Also see the sentimental analysis on Indian investors investing in Mersana Therapeutics Inc. Get details on the Indian mutual funds that are investing in Mersana Therapeutics Inc. Get Analyst recommendations and forecasts along with all the Mersana Therapeutics Inc's financials.

Mersana Therapeutics Inc share price movements

$2.30
$2.54
$2.53
9.09%
Downside
Day's Volatility :9.43%
Upside
0.37%
$1.22
$6.28
$2.53
51.78%
Downside
52 Weeks Volatility :80.57%
Upside
59.71%

Mersana Therapeutics Inc Returns

Period	Mersana Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	54.67%	-5.7%	0.0%
6 Months	4.5%	-0.9%	0.0%
1 Year	17.17%	10.0%	0.0%
3 Years	-63.12%	9.3%	-21.5%

Mersana Therapeutics Inc Key Statistics

in dollars & INR

Previous Close	$2.32
Open	$2.33
Today's High	$2.5394
Today's Low	$2.3
Market Capitalization	$280.4M
Today's Volume	$833.4K
52 Week High	$6.2801
52 Week Low	$1.22
Revenue TTM	$34.8M
EBITDA	$-77.8M
Earnings Per Share (EPS)	$-0.57
Profit Margin	-214.2%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-213.33%

How to invest in Mersana Therapeutics Inc from India?

It is very easy for Indian residents to invest directly in Mersana Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mersana Therapeutics Inc stock in both rupees (INR) and dollars (USD). Search for Mersana Therapeutics Inc or MRSN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mersana Therapeutics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mersana Therapeutics Inc shares which would translate to 0.335 fractional shares of Mersana Therapeutics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Mersana Therapeutics Inc

-3%

Period: Sep 8, 2024 to Dec 7, 2024. Change in 30 Days versus previous period

Search volume for Mersana Therapeutics Inc on INDmoney from India has reduced in the last 30 days as on Dec 8, 2024. -3% less investors are searching Mersana Therapeutics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Mersana Therapeutics Inc

EcoR1 Capital, LLC
15.68%
Nextech Invest AG
9.77%
VR Adviser, LLC
9.17%
Bain Capital Life Sciences Investors, LLC
7.01%
BlackRock Inc
6.79%
Vanguard Group Inc
5.81%

Analyst Recommendation on Mersana Therapeutics Inc

Buy

80%Buy

20%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Mersana Therapeutics Inc(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Mersana Therapeutics Inc

What analysts predicted

Upside of 156.92%

Current:

$2.53

Target:

$6.50

Insights on Mersana Therapeutics Inc

Increasing Revenue
Revenue is up for the last 2 quarters, 2.29M → 12.59M (in $), with an average increase of 81.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -24.26M → -11.50M (in $), with an average increase of 111.0% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 42.1% return, outperforming this stock by 28.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.7% return, outperforming this stock by 102.2%

Mersana Therapeutics Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$10.6M	↓ 39.62%
Net Income	$-64.3M	↑ 66.01%
Net Profit Margin	-606.54%	↓ 385.92%

	FY19	Y/Y Change
Revenue	$42.1M	↑ 297.61%
Net Income	$-27.2M	↓ 57.67%
Net Profit Margin	-64.57%	↑ 541.97%

	FY20	Y/Y Change
Revenue	$828.0K	↓ 98.03%
Net Income	$-88.4M	↑ 225.05%
Net Profit Margin	-10.7K%	↓ 10612.24%

	FY21	Y/Y Change
Revenue	$43.0K	↓ 94.81%
Net Income	$-169.2M	↑ 91.4%
Net Profit Margin	-393.5K%	↓ 382823.19%

	FY22	Y/Y Change
Revenue	$26.6M	↑ 61716.28%
Net Income	$-207.5M	↑ 22.66%
Net Profit Margin	-780.78%	↑ 392719.22%

	FY23	Y/Y Change
Revenue	$36.9M	↑ 38.65%
Net Income	$-171.7M	↓ 17.28%
Net Profit Margin	-465.8%	↑ 314.98%

	Q2 FY23	Q/Q Change
Revenue	$10.7M	↑ 36.55%
Net Income	$-54.3M	↓ 4.97%
Net Profit Margin	-509.73%	↑ 222.72%

	Q3 FY23	Q/Q Change
Revenue	$7.7M	↓ 27.75%
Net Income	$-41.7M	↓ 23.3%
Net Profit Margin	-541.13%	↓ 31.4%

	Q4 FY23	Q/Q Change
Revenue	$10.7M	↑ 39.01%
Net Income	$-19.5M	↓ 53.08%
Net Profit Margin	-182.64%	↑ 358.49%

	Q1 FY24	Q/Q Change
Revenue	$9.2M	↓ 13.61%
Net Income	$-19.3M	↓ 1.22%
Net Profit Margin	-208.83%	↓ 26.19%

	Q2 FY24	Q/Q Change
Revenue	$2.3M	↓ 75.2%
Net Income	$-24.3M	↑ 25.7%
Net Profit Margin	-1.1K%	↓ 849.52%

	Q3 FY24	Q/Q Change
Revenue	$12.6M	↑ 449.41%
Net Income	$-11.5M	↓ 52.61%
Net Profit Margin	-91.29%	↑ 967.06%

	FY18	Y/Y Change
Total Assets	$78.5M	↓ 39.94%
Total Liabilities	$69.7M	↑ 14.8%

	FY19	Y/Y Change
Total Assets	$107.5M	↑ 36.99%
Total Liabilities	$29.2M	↓ 58.08%

	FY20	Y/Y Change
Total Assets	$273.4M	↑ 154.23%
Total Liabilities	$45.3M	↑ 55.06%

	FY21	Y/Y Change
Total Assets	$206.1M	↓ 24.61%
Total Liabilities	$84.4M	↑ 86.2%

	FY22	Y/Y Change
Total Assets	$334.3M	↑ 62.21%
Total Liabilities	$242.3M	↑ 187.17%

	FY23	Y/Y Change
Total Assets	$226.1M	↓ 32.39%
Total Liabilities	$189.2M	↓ 21.93%

	Q2 FY23	Q/Q Change
Total Assets	$311.0M	↑ 5.0%
Total Liabilities	$221.2M	↓ 4.61%

	Q3 FY23	Q/Q Change
Total Assets	$262.9M	↓ 15.46%
Total Liabilities	$210.7M	↓ 4.74%

	Q4 FY23	Q/Q Change
Total Assets	$226.1M	↓ 14.01%
Total Liabilities	$189.2M	↓ 10.23%

	Q1 FY24	Q/Q Change
Total Assets	$198.4M	↓ 12.25%
Total Liabilities	$170.4M	↓ 9.92%

	Q2 FY24	Q/Q Change
Total Assets	$179.1M	↓ 9.7%
Total Liabilities	$170.7M	↑ 0.18%

	Q3 FY24	Q/Q Change
Total Assets	$169.5M	↓ 5.36%
Total Liabilities	$168.5M	↓ 1.3%

	FY18	Y/Y Change
Operating Cash Flow	$-55.2M	↑ 29.38%
Investing Cash Flow	$87.2M	↓ 187.52%
Financing Cash Flow	$1.1M	↓ 98.45%

	FY19	Y/Y Change
Operating Cash Flow	$-67.7M	↑ 22.69%
Investing Cash Flow	$-27.3M	↓ 131.3%
Financing Cash Flow	$97.7M	↑ 9082.71%

	FY20	Y/Y Change
Operating Cash Flow	$-74.7M	↑ 10.26%
Investing Cash Flow	$37.0M	↓ 235.66%
Financing Cash Flow	$230.4M	↑ 135.83%

	FY21	Y/Y Change
Operating Cash Flow	$-140.0M	↑ 87.41%
Investing Cash Flow	$-648.0K	↓ 101.75%
Financing Cash Flow	$63.6M	↓ 72.38%

	FY22	Y/Y Change
Operating Cash Flow	$-49.4M	↓ 64.74%
Investing Cash Flow	$-152.7M	↑ 23467.28%
Financing Cash Flow	$153.0M	↑ 140.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-61.8M	↑ 113.18%
Investing Cash Flow	$-5.4M	↓ 489.61%
Financing Cash Flow	$73.2M	↑ 239.6%

Mersana Therapeutics Inc Technicals Summary

Sell

Neutral

Buy

Mersana Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Mersana Therapeutics Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mersana Therapeutics Inc	-9.73%	4.5%	17.17%	-63.12%	-41.78%
Regeneron Pharmaceuticals, Inc.	-6.86%	-23.34%	-9.49%	15.35%	108.86%
Biontech Se	10.16%	21.29%	18.26%	-58.19%	324.43%
Alnylam Pharmaceuticals, Inc.	-7.5%	64.08%	47.33%	46.0%	106.67%
Vertex Pharmaceuticals Incorporated	-8.46%	-4.83%	29.09%	120.68%	108.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mersana Therapeutics Inc	NA	NA	0.0	-0.59	-2.13	-0.26	NA	0.31
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mersana Therapeutics Inc	Buy	$280.4M	-41.78%	NA	-214.2%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	108.86%	18.56	33.61%
Biontech Se	Buy	$28.5B	324.43%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	106.67%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	108.8%	32.84	-4.51%

About Mersana Therapeutics Inc

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Organization	Mersana Therapeutics Inc
Employees	123
CEO	Dr. Martin H. Huber M.D.
Industry	Health Technology

Management People of Mersana Therapeutics Inc

Name	Title
Dr. Martin H. Huber M.D.	President, CEO & Director
Mr. Brian C. DeSchuytner	Senior VP, CFO & COO
Dr. Timothy B. Lowinger Ph.D.	Senior VP and Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D.	Senior VP, Secretary & Chief Legal Officer
Mr. Mohan Bala Ph.D.	Senior VP & Chief Development Officer
Mr. Mikhail Papisov Ph.D.	Co-Founder
Mr. Ashish Mandelia	Chief Accounting Officer
Mr. Jason Fredette	Senior Vice President of Investor Relations & Corporate Communications
Mr. Chuck Miller	Senior Vice President of Regulatory Affairs
Mr. Marc Damelin	Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.

Important FAQs about investing in Mersana Therapeutics Inc from India :

What is Mersana Therapeutics Inc share price today?

Mersana Therapeutics Inc (MRSN) share price today is $2.53.

Can Indians buy Mersana Therapeutics Inc shares?

Yes, Indians can invest in the Mersana Therapeutics Inc (MRSN) from India.

With INDmoney, you can buy Mersana Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Mersana Therapeutics Inc at zero transaction cost.

How can I buy Mersana Therapeutics Inc shares from India?

It is very easy to buy Mersana Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Mersana Therapeutics Inc be purchased?

Yes, you can buy fractional shares of Mersana Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Mersana Therapeutics Inc stocks?

To start investing in Mersana Therapeutics Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.